YIH
PACB icon

Y-Intercept (HK)’s Pacific Biosciences PACB Stock Holding History

Y-Intercept (HK)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-76,692
Closed -$752K – 1654
2023
Q4 		$752K Buy
+76,692
New +$627K 0.07% 429
2023
Q3 		– Sell
-53,218
Closed -$708K – 1453
2023
Q2 		$708K Sell
53,218
-7,545
-12% -$91.7K 0.07% 418
2023
Q1 		$704K Buy
+60,763
New +$604K 0.08% 382
2021
Q2 		– Sell
-17,256
Closed -$517K – 818
2021
Q1 		$517K Buy
+17,256
New +$604K 0.14% 249

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Y-Intercept (HK)'s PACB Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 76,692 shares — an estimated $752K sold.

Y-Intercept (HK) first reported a position in PACB in Q1 2021 and held it in 4 quarters. The position peaked at $752K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 76,692 Pacific Biosciences shares in Q1 2024, an estimated $752K.
  • Y-Intercept (HK) first reported a position in Pacific Biosciences in Q1 2021 and held it in 4 quarters.
  • Y-Intercept (HK)'s Pacific Biosciences position peaked at $752K in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.